Naturalistic study of antipsychotic long-acting use in the SPDC of Rome and Lazio;Studio naturalistico sull'impiego degli antipsicotici nella formulazione long-acting negli SPDC di Roma e del Lazio

Rivista di Psichiatria

Volumn 40, Issue 4, 2005, Pages 220-233

  Pacitti, Francesca ^a   Iannitelli, Angela ^b   Bersani, Giuseppe ^b  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Antipsychotic; Bipolar disorder; Depot; Naturalistic study; Pharmacotherapy; Schizoaffective disorder; Schizophrenia

Indexed keywords

FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; PENFLURIDOL; PERPHENAZINE; RISPERIDONE; ZUCLOPENTHIXOL;

ADULT; AGGRESSION; ARTICLE; BIPOLAR DISORDER; CLINICAL FEATURE; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DRUG EFFICACY; FEMALE; HUMAN; ITALY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSESSIVE COMPULSIVE DISORDER; PATIENT COMPLIANCE; PERSONALITY DISORDER; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 25144437399     PISSN: 00356484     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Kane JM: Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. Journal of Clinical Psychiatry, 2003, 64, suppl. 16, 34-40.
2. Marland GR, Sharkey V: Depot neuroleptics, schizophrenia and the role of the nurse: is practice evidence based? A review of the literature. Journal of Advanced Nursing, 1999, 30, 1255-1262.
3. Keith SJ, Kane JM, Turner M, Conley RR, Nasrallah HA: Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics. Journal of Clinical Psychiatry, 2004, 65, 120-131.
4. Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca PM, Chrzanowski W, et al.: Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trila of the first long-acting second-generation antipsychotic. Journal of Clinical Psychiatry, 2003, 64, 1250-1257.
5. Keks N, Been C, D'Souza R, Thomas R, Tune P, Babb J, et al.: Initial experience with long-acting risperidone microspheres injection. Australasian Psychiatry, 2003, 11, 273-275.
6. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K: Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. American Journal of Psychiatry, 2003, 160, 1125-1132.
7. Love RC, Conley RJ: American Journal of Health-System Pharmachology, 2004, 61, 1792-1800.
8. Marder S: Overview of partial compliance. Journal of Clinical Psychiatry, 2003, 64, suppl. 16, 3-9.
9. Patel MX, Nikolau V, David AS: Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Psychological Medicine, 2003, 33, 83-89.
10. Kane JM, Conley RR, Keith SJ, Nasrallah HA, Turner M: Guidelines for the use of long-acting injectable atypical antipsychotics. Journal of Clinical Psychiatry, 2004, 65, 120-131.
11. Adams CE, Fenton MKP, Quraishi S, Davis AS: Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. British Journal of Psychiatry, 2001, 179, 290-299.
12. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fourth edition, text revision (DSM-IV TR). American Psychiatric Association, Washington, D.C., 2000.
13. Quraishi S, David A: Depot haloperidol decanoate for schizophrenia (Cochrane Review). In: Cochrane Library, Issue 4, 2003. Chichester, UK, John Wiley and Sons, Ltd.
14. Adams CE, Eisenbruch M: Depot fluphenazine for schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 4, 2003. Chichester, U K, John Wiley and Sons, Ltd.
15. Hosalli P, Davis JM: Depot risperidone for schizophrenia. Cochrane Database of Systematic Reviews, 2003, 4, CD004161.
16. Coutinho E, Fenton M, Quraishi S: Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses (cochrane Review). In: The Cochrane Library, Issue 4, 2003. Chichester, UK, John Wiley and Sons, Ltd.
17. David A, Quraishi S: Depot perphenazine decanoate and enanthate for schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 4,2003, Chichester, UK, John Wiley and Sons, Ltd.
18. Quraishi S, David A: Depot flupenthixol decanoate for schizophrenia or other similar psychotic disorders. Cochrane Database of Systematic Reviews, 2000, 2, CD001470.
19. Arnold LM, Strakowski SM, Schwiers ML, Amicone J, Fleck DE, Corey KB, et al.: Sex, ethnicity, and antipsychotic medication use in patients with psychosis. Schizophrenia Research, 2004, 66, 169-175.
20. Kane JM, Aguglia E, Aktamura AC, Gutierrez JLA, Brunello N, Fleischhacker WW, et al.: Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology, 1998, 8, 55-66.
21. Harris NR, Lovell K, Day JC: Consent and long-term neuroleptic treatment. Journal of Psychiatric and Mental Health Nursing, 2002, 9, 475-482.
22. Lasser RA, Bossie CA, Gharabawi GM, Turner M: Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. European Psychiatry, 2004, 19, 219-225.